Cantuzumab ravtansine

Drug Profile

Cantuzumab ravtansine

Alternative Names: C-242 DM4; C242 DM4 immunoconjugate; C242 maytansinoid-4 conjugate; huC242-DM4; IMGN-242; Maytasinoid DM4-conjugated humanised monoclonal antibody huC242; Monoclonal antibody C-242 DM4 conjugate

Latest Information Update: 15 Jun 2009

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ImmunoGen
  • Class Antineoplastics; Immunoconjugates; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Gastric cancer; Solid tumours

Most Recent Events

  • 12 Jun 2009 Discontinued - Phase-I for Solid tumours in USA (IV)
  • 12 Jun 2009 Discontinued - Phase-II for Gastric cancer in USA (IV)
  • 25 Oct 2007 Data presented at the 19th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2007) added to the adverse events and Cancer therapeutic trials and pharmacodynamics sections ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top